Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

AstraZeneca trial shows benefit of child asthma treatment

Friday, November 11, 2016 8:38
% of readers think this story is Fact. Add your two cents.

A phase III study of its Symbicourt asthma inhalers showed a significant breathing improvement in children aged between 6-12, AstraZeneca reported (LON:AZN).

The improvement demonstrated the drug’s appropriateness as a step-up therapy in young children, Astra said.

AstraZeneca conducted the study (CHASE 3) after the US Food and Drug Administration (FDA) requested additional data on the effect of the two components budesonide and formoterol in young asthma patients.

Gregory Keenan, Vice President, Medical Affairs and US Head Medical Officer, said: “These safety and efficacy results from the CHASE 3 study indicate Symbicourt may offer an important asthma treatment option for the appropriate pediatric populations.

“We look forward to working with the regulatory authorities to help make Symbicourt available to this population of children with asthma.”

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.